Approval Date: May 16, 1995

Freedom of Information Summary
NADA 200-139

I. GENERAL INFORMATION:

NADA	200-139
Sponsor:	Chanelle Pharmaceutical Manufacturing Ltd. Loughrea, County Galway Ireland
Generic Name:	xylazine hydrochloride
Trade Name:	Chanazine® 100 mg/mL Injectable
Marketing Status:	Prescription

2. TARGET ANIMAL SAFETY AND DRUG EFFECTIVENESS:

Under the provisions of the Federal Food, Drug, and Cosmetic Act, as amended by the Generic Animal Drug and Patent Term Restoration Act, (53 FR 50460, December 15, 1988; First GADPTRA Policy Letter), an Abbreviated New Animal Drug Application (ANADA) may be submitted for a genetic version of an approved new animal drug (pioneer product). For certain dosage forms, the Agency grants a waiver from conducting an in vivo bioequivalence study (55 FR 24645, June 18, 1990; Fifth GADPTRA Policy Letter). In lieu of bioequivalence testing, the safety and efficacy of the generic product are based on the demonstrated chemical equivalence to the pioneer product.

Based on the formulation characteristics of the genetic product, Chanelle Manufacturing Pharmaceutical, Ltd. was granted a waiver November 26, 1991 (photocopy attached) from conducting an in vivo bioequivalence study with Chanazine® 100 mg/mL Injectable. The generic and pioneer products are solutions with the same inactive ingredients and the same concentrations of the active ingredient. It is intended solely for intravenous and intramuscular injection.

3. HUMAN SAFETY:

Human Safety Relative to Food Consumption:

Regarding consumption of drug residues in food, human safety data were not required for approval of this ANADA. This drug is labeled for use in horses and Cervidae only and should not be administered to food-producing animals.

 

Human Safety Relative to Possession, Handling, and Administration:

Labeling contains adequate caution/warning statements.

4. AGENCY CONCLUSIONS:

This is an Abbreviated New Animal Drug Application (ANADA) filed under Section 512(b)(2) of the Federal, Food, Drug and Cosmetic (FFD&C) Act.

Safety and effectiveness for this genetic animal drug, Chanazine® 100 mg/mL Injectable, were established by demonstration of chemical equivalence to the pioneer product, Bayers' Rompun® 100 mg/mL Injectable (xylazine hydrochloride, 100 mg/mL, NADA 047-956).

This generic product and the pioneer product have identical labeling indications for use. The route and method of administration of the two drugs are identical. Both drugs are administered by intravenous or intramuscular injection. The generic and pioneer products are both solutions that contain the same active and inactive ingredients in the same concentrations. Both products have the same pH. Therefore, consistent with FDA policy implementing Section 512(b)(2) of the FFD&C Act, no additional safety, efficacy, or in vivo bioequivalency studies were necessary or required.

This ANADA satisfies the requirements of section 512 of the Act and demonstrates that Chanazine is safe and effective for its labeled indications when used under its proposed conditions of use.

Attachments:

1. Generic Labeling:

Package Insert
Immediate Container Label

2. Pioneer Labeling:

Package Insert-Horses
Package Insert-Cervidae
Carton Label
Bottle Label
Shipping Carton Label

3. Copy of waiver letter dated November 26, 1991

Copies of applicable labels may be obtained by writing to the:

Freedom of Information Office
Center for Veterinary Medicine, FDA
7500 Standish Place
Rockville, MD 20855

---